NO20026012D0 - HMG-CoA-reduktase-inhibitorer og metode - Google Patents
HMG-CoA-reduktase-inhibitorer og metodeInfo
- Publication number
- NO20026012D0 NO20026012D0 NO20026012A NO20026012A NO20026012D0 NO 20026012 D0 NO20026012 D0 NO 20026012D0 NO 20026012 A NO20026012 A NO 20026012A NO 20026012 A NO20026012 A NO 20026012A NO 20026012 D0 NO20026012 D0 NO 20026012D0
- Authority
- NO
- Norway
- Prior art keywords
- hmg
- coa reductase
- reductase inhibitors
- inhibitors
- coa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21159500P | 2000-06-15 | 2000-06-15 | |
PCT/US2001/018864 WO2001096347A1 (en) | 2000-06-15 | 2001-06-12 | HMG-CoA REDUCTASE INHIBITORS AND METHOD |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20026012D0 true NO20026012D0 (no) | 2002-12-13 |
NO20026012L NO20026012L (no) | 2003-02-03 |
Family
ID=22787569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20026012A NO20026012L (no) | 2000-06-15 | 2002-12-13 | HMG-CoA-reduktase-inhibitorer og fremgangsmåte |
Country Status (22)
Country | Link |
---|---|
US (1) | US20020013334A1 (no) |
EP (1) | EP1294728A1 (no) |
JP (1) | JP2004503557A (no) |
KR (1) | KR20030036225A (no) |
CN (1) | CN1436192A (no) |
AR (1) | AR030700A1 (no) |
AU (1) | AU2001266858A1 (no) |
BR (1) | BR0111599A (no) |
CA (1) | CA2412632A1 (no) |
CZ (1) | CZ20023930A3 (no) |
EC (1) | ECSP024384A (no) |
HU (1) | HUP0302937A2 (no) |
IL (1) | IL152490A0 (no) |
MX (1) | MXPA02012252A (no) |
NO (1) | NO20026012L (no) |
NZ (1) | NZ523627A (no) |
PE (1) | PE20020254A1 (no) |
PL (1) | PL359820A1 (no) |
RU (1) | RU2003101064A (no) |
UY (1) | UY26777A1 (no) |
WO (1) | WO2001096347A1 (no) |
ZA (1) | ZA200210103B (no) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1305046A2 (en) * | 2000-07-20 | 2003-05-02 | Bristol-Myers Squibb Company | Regulators of ppardelta (beta) and their use in the treatment of obesity and insulin resistance |
WO2002051441A1 (fr) * | 2000-12-26 | 2002-07-04 | Sankyo Company, Limited | Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline |
EP1864680A3 (en) * | 2001-01-26 | 2012-03-28 | Schering Corporation | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
CN1658903A (zh) * | 2001-01-26 | 2005-08-24 | 先灵公司 | 用于治疗血管性疾病的固醇吸收抑制剂与血液调节剂的组合 |
US20020183305A1 (en) * | 2001-01-26 | 2002-12-05 | Schering Corporation | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
BR0206644A (pt) * | 2001-01-26 | 2004-02-25 | Schering Corp | Combinações de inibidor(es) de absorção de esteróis com agente(s) cardiovascular(es) para o tratamento de condições vasculares |
PL367133A1 (en) * | 2001-06-06 | 2005-02-21 | Bristol-Myers Squibb Company | Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors |
GB0119460D0 (en) * | 2001-08-09 | 2001-10-03 | Ark Therapeutics Ltd | The use of inhibitors of the renin-angiotensin system |
CN1585638A (zh) | 2001-09-14 | 2005-02-23 | 图拉里克公司 | 被连接的联芳基化合物 |
MXPA04006203A (es) | 2001-12-21 | 2004-10-15 | Pharmacia Corp | Moduladores aromaticos del receptor x de higado de tioeter. |
US20060058369A1 (en) * | 2002-02-19 | 2006-03-16 | Vanderbilt University | Therapeutic methods employing PAI-1 inhibitors and transgenic non-human animal for screening candidate PAI-1 inhibitors |
US7705182B2 (en) | 2002-02-28 | 2010-04-27 | University Of Tennessee Research Foundation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
US20030171407A1 (en) * | 2002-03-07 | 2003-09-11 | Upsher-Smith Laboratories, Inc. | Composition for reducing blood glucose and cholesterol |
WO2003077825A2 (en) * | 2002-03-12 | 2003-09-25 | Microdose Technologies, Inc. | Site specific delivery of co-administered drugs via inhalation |
US20040005358A1 (en) * | 2002-04-23 | 2004-01-08 | Slugg Peter H. | Modified-release vasopeptidase inhibitor formulation, combinations and method |
CA2486651A1 (en) * | 2002-05-24 | 2003-12-04 | Pharmacia Corporation | Sulfone liver x-receptor modulators |
US6900244B2 (en) * | 2002-05-24 | 2005-05-31 | Pharmacia Corporation | Anilino liver X-receptor modulators |
US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
JP2006501205A (ja) * | 2002-07-30 | 2006-01-12 | カリキオン インコーポレイテッド | エゼチミブ組成物、並びにコレステロールに関連した良性および悪性の腫瘍を治療する方法 |
CA2494061C (en) * | 2002-07-31 | 2011-06-14 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
MXPA05002914A (es) * | 2002-09-17 | 2005-05-27 | Pharmacia Corp | Moduladores de los receptores x hepaticos aromaticos. |
EP1551824B1 (en) * | 2002-10-09 | 2007-12-12 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
US7507531B2 (en) | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
GB0228894D0 (en) * | 2002-12-11 | 2003-01-15 | Avecia Ltd | Process |
EP1587584B1 (de) * | 2003-01-16 | 2007-05-23 | Boehringer Ingelheim International GmbH | Pharmazeutische kombination zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten |
DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
DE602004016123D1 (de) | 2003-03-07 | 2008-10-09 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
ATE418551T1 (de) | 2003-03-07 | 2009-01-15 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
TWI393560B (zh) * | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
WO2004108126A1 (en) * | 2003-06-06 | 2004-12-16 | Snowden Pharmaceuticals, Llc | Fibric acid derivatives for the treatment of irritable bowel syndrome |
BRPI0412262A (pt) * | 2003-07-23 | 2006-09-19 | X Ceptor Therapeutics Inc | derivados de azepina como agentes farmacêuticos |
US20080058292A1 (en) * | 2003-10-29 | 2008-03-06 | Raif Tawakol | Method for increasing HDL and HDL-2b levels |
PL1750862T3 (pl) * | 2004-06-04 | 2011-06-30 | Teva Pharma | Kompozycja farmaceutyczna zawierająca irbesartan |
US20060058283A1 (en) * | 2004-09-15 | 2006-03-16 | Zymes, Inc. | Compositions comprising ubiquinones |
US20070185065A1 (en) * | 2006-02-03 | 2007-08-09 | Vikramjit Chhokar | Combination therapy for coronary artery disease |
US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
WO2008059519A2 (en) * | 2006-09-25 | 2008-05-22 | Glenmark Pharmaceuticals Limited | A process for the preparation of intermediates of rosuvastatin |
CA2673683C (en) | 2007-01-11 | 2014-07-29 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
KR100900044B1 (ko) | 2007-07-05 | 2009-06-01 | 한국식품연구원 | 3-하이드록시-3-메틸글루타릴 보조효소 a 환원효소 저해용펩타이드 및 이를 함유하는 고콜레스테롤로 인한 심장질환 및 심혈관계 질환 치료제 |
WO2009079765A1 (en) * | 2007-12-21 | 2009-07-02 | Cascade Therapeutics Inc. | Compounds with activity at the 5-ht2c receptor |
CA2710039C (en) * | 2007-12-26 | 2018-07-03 | Critical Outcome Technologies, Inc. | Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer |
BRPI0821962A2 (pt) * | 2008-01-03 | 2019-05-07 | Univ De La Mediterrannee Aix Marseille Ii | composições e métodos usados durante um tratamento anti-hiv |
EP3023426A1 (en) | 2008-07-17 | 2016-05-25 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
KR20120122869A (ko) * | 2009-06-02 | 2012-11-07 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 신경변성 질환을 갖는 대상에서 항체에 의해 인식되는 소분자의 확인법 |
CN105381524A (zh) | 2010-01-05 | 2016-03-09 | 微剂量治疗技术公司 | 吸入设备和方法 |
EP2552915B1 (en) | 2010-04-01 | 2017-07-19 | Critical Outcome Technologies Inc. | Compounds for the treatment of hiv |
CN105153010B (zh) * | 2010-07-01 | 2018-06-08 | 柳韩洋行 | HMG-CoA还原酶抑制剂及其中间体的制备方法 |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
CN103360384A (zh) * | 2013-07-30 | 2013-10-23 | 浙江京新药业股份有限公司 | HMG-CoA还原酶抑制剂关键中间体的合成方法 |
CN106822903B (zh) * | 2017-02-13 | 2019-07-23 | 牡丹江医学院 | 用于治疗心衰的药物组合物及其应用 |
CN107164544A (zh) * | 2017-07-18 | 2017-09-15 | 孙葆青 | 通过高通量测序快速检测阿托伐他汀钙的敏感性的方法 |
WO2019208740A1 (ja) | 2018-04-27 | 2019-10-31 | 三ツ星ベルト株式会社 | Vリブドベルト及びその用途 |
CN110747206B (zh) * | 2019-11-05 | 2021-11-23 | 昆明理工大学 | 3-羟基-3-甲基戊二酸单酰辅酶a还原酶基因rkhmgr及其应用 |
CN114213350B (zh) * | 2021-12-29 | 2024-03-19 | 江苏福瑞康泰药业有限公司 | 一种他汀类药物中间体的制备方法 |
CN114437052B (zh) * | 2021-12-31 | 2024-03-29 | 江苏阿尔法集团福瑞药业(宿迁)有限公司 | 一种利用连续流微通道反应器合成他汀类药物中间体的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO177005C (no) * | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
US5506219A (en) * | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
US5753675A (en) * | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
ZA911046B (en) * | 1990-02-26 | 1992-10-28 | Squibb & Sons Inc | Quinoline and pyridine anchors for hmg-coa reductase inhibitors |
US5177080A (en) * | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
DE19627431A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
-
2001
- 2001-06-06 US US09/875,155 patent/US20020013334A1/en not_active Abandoned
- 2001-06-12 WO PCT/US2001/018864 patent/WO2001096347A1/en not_active Application Discontinuation
- 2001-06-12 HU HU0302937A patent/HUP0302937A2/hu unknown
- 2001-06-12 BR BR0111599-5A patent/BR0111599A/pt not_active IP Right Cessation
- 2001-06-12 EP EP01944447A patent/EP1294728A1/en not_active Withdrawn
- 2001-06-12 IL IL15249001A patent/IL152490A0/xx unknown
- 2001-06-12 PL PL35982001A patent/PL359820A1/xx not_active Application Discontinuation
- 2001-06-12 KR KR1020027017086A patent/KR20030036225A/ko not_active Application Discontinuation
- 2001-06-12 RU RU2003101064/04A patent/RU2003101064A/ru not_active Application Discontinuation
- 2001-06-12 CZ CZ20023930A patent/CZ20023930A3/cs unknown
- 2001-06-12 AU AU2001266858A patent/AU2001266858A1/en not_active Abandoned
- 2001-06-12 MX MXPA02012252A patent/MXPA02012252A/es unknown
- 2001-06-12 JP JP2002510488A patent/JP2004503557A/ja active Pending
- 2001-06-12 NZ NZ523627A patent/NZ523627A/en unknown
- 2001-06-12 CA CA002412632A patent/CA2412632A1/en not_active Abandoned
- 2001-06-12 CN CN01811211A patent/CN1436192A/zh active Pending
- 2001-06-15 PE PE2001000578A patent/PE20020254A1/es not_active Application Discontinuation
- 2001-06-15 AR ARP010102886A patent/AR030700A1/es not_active Application Discontinuation
- 2001-06-15 UY UY26777A patent/UY26777A1/es not_active Application Discontinuation
-
2002
- 2002-12-12 ZA ZA200210103A patent/ZA200210103B/xx unknown
- 2002-12-13 EC EC2002004384A patent/ECSP024384A/es unknown
- 2002-12-13 NO NO20026012A patent/NO20026012L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2001266858A1 (en) | 2001-12-24 |
IL152490A0 (en) | 2003-05-29 |
NO20026012L (no) | 2003-02-03 |
CN1436192A (zh) | 2003-08-13 |
JP2004503557A (ja) | 2004-02-05 |
AR030700A1 (es) | 2003-09-03 |
ECSP024384A (es) | 2003-03-31 |
NZ523627A (en) | 2004-10-29 |
WO2001096347A1 (en) | 2001-12-20 |
HUP0302937A2 (hu) | 2003-12-29 |
KR20030036225A (ko) | 2003-05-09 |
EP1294728A1 (en) | 2003-03-26 |
CA2412632A1 (en) | 2001-12-20 |
UY26777A1 (es) | 2002-01-31 |
PL359820A1 (en) | 2004-09-06 |
PE20020254A1 (es) | 2002-04-03 |
US20020013334A1 (en) | 2002-01-31 |
ZA200210103B (en) | 2004-03-12 |
MXPA02012252A (es) | 2003-06-06 |
RU2003101064A (ru) | 2004-08-10 |
CZ20023930A3 (cs) | 2003-03-12 |
BR0111599A (pt) | 2004-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20026012D0 (no) | HMG-CoA-reduktase-inhibitorer og metode | |
NO20026011D0 (no) | HMG-CoA-reduktase-inhibitorer og fremgangsmåte | |
NO20014823D0 (no) | Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode | |
EP1684754A4 (en) | HMG COA REDUCTASE INHIBITORS AND METHOD | |
NO20032668L (no) | Gyraseinhibitorer og anvendelser derav | |
NO20044915L (no) | C-aryl-glukosid SGLT2 inhibitorer og metode | |
NO20052779D0 (no) | Doseringsformer omfattende en CETP-inhibitor og en HMG-CoA-reduktaseinhibitor. | |
DE60211317D1 (de) | Rho-kinase inhibitoren | |
DE60218138D1 (de) | Rho-kinase inhibitoren | |
DK1373259T3 (da) | Pyridazinonaldosereduktaseinhibitorer | |
DK1223918T3 (da) | Farmaceutiske præparater omfattende en HMG-CoA-reductaseinhibitor | |
NO20025416L (no) | System og fremgangsmåte ved ekspanderbar komplettering | |
NO20015492D0 (no) | Fremgangsmåte og anordning for flersidig forbindelse | |
ATE269701T1 (de) | Gyrase-inhibitoren und ihre verwendung | |
DK1339292T3 (da) | Sammensætning og fremgangsmåde | |
NO20040865L (no) | Friksjon reduserende sammensetning og metode | |
NO20033854D0 (no) | N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse | |
IS6691A (is) | Aðferð og algoritmi til að greina mRNA tjáningu | |
ATE502118T1 (de) | Amplifizierungsverfahren | |
FI20000715A0 (fi) | Ryhmätyömenetelmä ja -järjestelmä | |
DE60231591D1 (de) | Aufzeichnungsvorrichtung und -verfahren | |
DE60135813D1 (de) | CDMA Empfangsgerät und -verfahren | |
AU6045801A (en) | Inhibitor function check method and apparatus | |
DK1307761T3 (da) | Fremgangsmåde til retningsbestemmelse og bestemmelsesapparat | |
AU5258701A (en) | Method of searching for arteriosclerosis inhibitors and shrinkers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |